REMARKS

In response to the restriction request, the applicants make an election of Examiner's Group III and Claims 1 - 11 have been amended into a more traditional method of treatment format.

So far as the election of species requirement is concerned, should no generic claim be found to be allowable, the applicant elects the sodium channels of Claim 3 as the location of action and the blocking agents of Claim 5, and more specifically carbamazepine (claimed in Claims 6 and 20) as the blocking agent. Claims 1 and 15 are generic to sodium channels as being the location of action and Claims 1,5, 15, 18, and 19 to carbamazepine-as the blocking agent.

Respectfully submitted,

JOHN/KICH/ARDS

C/O/LADAS & PARRY LLP

26 WEST 61ST STREET

NEW YORK, NEW YORK 10023

REG. NO. 31053

TEL. NO. (212) 708-1890